Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q2 2023 · 10-Q
Revenue$1.87M$1.87M+22.3% vs Q2 2022 Net Income-$29.57M-$29.57MN/M vs Q2 2022 EPS Diluted-$0.42-$0.42N/M vs Q2 2022 Operating Income-$31,815,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$20,885,000N/M Margins · derivedOperating margin-1702.2%−328.3 pt vs Q2 2022
Net margin-1582.1%−238.4 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 7, 2023 · 38 d after period end